Studies of efficacy and safety of the combined use of febuxostat and inosine for patients with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis, and changes of blood and urine purine compounds.

Studies of efficacy and safety of the combined use of febuxostat and inosine for patients with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis, and changes of blood and urine purine compounds. - Effect of febuxostat and inosine on CNS diseases

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024312

Enrollment

Registered

2017-05-25

Start date

2016-09-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer&#39

Interventions

Treatment with febuxostat 20 mg and inosine 0.5 g, twice a day for 2 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Japanese with 20 to 80 years of age 2. Patients diagnosed as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis by specialist doctors.

Exclusion criteria

Exclusion criteria: 1. Subjects taking azathioprine or mercaptopurine 2. Subject who has or had renal function disorder. 3. Subject with a history of gout, hyperuricemia or urolithiasis. 4. Subject who has a history of renal disorder. 5. Subject who has or had hypersensitivity, idiosyncracy (allergy) to drug. 6. Subject who was judged not to be appropriate by the principal investigator or sub investigators by other reasons.

Design outcomes

Primary

Measure	Time frame
Changes of HDS-R (Alzheimer's disease), Yahr's classification (Parkinson's disease), EDSS (multiple sclerosis) and ALSFRS-R (amyotrophic lateral sclerosis) by 2-week treatment with febuxostat and inosine	—

Countries

Japan

Contacts

Public ContactMasanori Suzuki

Tsukuba International Clinical Pharmacology Clinic Division for Volunteers

m-suzuki@tsukuba-icp.jp029-839-1150

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Studies of efficacy and safety of the combined use of febuxostat and inosine for patients with Alzheimer&#39;s disease, Parkinson&#39;s disease, amyotrophic lateral sclerosis or multiple sclerosis, and changes of blood and urine purine compounds.